Adenovirus-mediated Ink4a/ARF gene transfer significantly suppressed the growth of pancreatic carcinoma cells

Cancer Biology and Therapy

Volumn 4, Issue 12, 2005, Pages 1348-1354

  Chen, Fang ^a   Li, Yiting ^a   Lu, Zhaohui ^a   Gao, Jie ^a   Chen, Jie ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Gene therapy; p14ARF; p16INK4a; Pancreatic carcinoma; Recombinant adenovirus vector

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN P14ARF; PROTEIN P16INK4A; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PHENOTYPE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

EID: 31144446196     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.12.2183     Document Type: Article

References (40)

1. Wang L, Yang GH, Lu XH, Huang ZJ, Li H. Pancreatic cancer mortality in china (1991-2000). World J Gastroenterol 2003; 9:1819-23.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
3. Ahrendt SA, Pitt HA. Surgical management of pancreatic cancer. Oncology (Huntingt) 2002; 16:725-34 (discussion 734, 736-8, 740, 743).
4. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: One gene - two products - two pathways. Trends Biochem Sci 1998; 23:291-6.
5. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368:753-6.
6. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 2:731-7.
7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-7.
8. Jin X, Nguyen D, Zhang WW, Kyritsis AP, Roth JA. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res 1995; 55:3250-3.
9. Craig C, Kim M, Ohri E, Wersto R, Katayose D, Li Z, Choi YH, Mudahar B, Srivastava S, Seth P, Cowan K. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and rb status in human cancer cells. Oncogene 1998; 16:265-72.
10. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the rb and p53 tumor suppression pathways. Cell 1998; 92:725-34.
11. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8:27-32.
12. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 1994; 91:11045-9.
13. Chen XL, Zhang QH, Ni QX. The relationship between tumor suppressor genes p14ARF and p53 expression and biological behavior of pancreatic carcinoma. Zhonghua Yi Xue Za Zhi 2003; 83:868-71.
14. Geradts J, Wilentz RE, Roberts H. Immunohistochemical [corrected] detection of the alternate INK4a-encoded tumor suppressor protein p14(ARF) in archival human cancers and cell lines using commercial antibodies: Correlation with p16(INK4a) expression. Mod Pathol 2001; 14:1162-8.
15. Voorhoeve PM, Agami R. Unraveling human tumor suppressor pathways: A tale of the INK4A locus. Cell Cycle 2004; 3:616-20.
16. Kobayashi S, Shirasawa H, Sashiyama H, Kawahira H, Kaneko K, Asano T, Ochiai T. P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation. Clin Cancer Res 1999; 5:4182-5.
17. Ghaneh P, Greenhalf W, Humphreys M, Wilson D, Zumstein L, Lemoine NR, Neoptolemos JP. Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001; 8:199-208.
18. Yang CT, You L, Lin YC, Lin CL, Mccormick F, Jablons DM. A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Res 2003; 23:33-8.
19. 2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene 2003; 22:1822-35.
20. Chen J, Liu TH, Guo XY. Two new human exocrine pancreatic adenocarcinoma cell lines in vitro and in vivo. Chinese Med J 1990; 103:369-75.
21. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92:9363-7.
22. Sunamura M, Yatsuoka T, Motoi F, Duda DG, Kimura M, Abe T, Yokoyama T, Inoue H, Oonuma M, Takeda K, Matsuno S. Gene therapy for pancreatic cancer based on genetic characterization of the disease. J Hepatobiliary Pancreat Surg 2002; 9:32-8.
23. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2:103-12.
24. Sakorafas GH, Tsiotou AG, Tsiotos GG. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 2000; 26:29-52.
25. Yu GZ, Zhu MH, Ni CR, Li FM, Zheng JM, Gong ZJ. Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma. Zhonghua Bing Li Xue Za Zhi 2004; 33:130-4.
26. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92:713-23.
27. Lohrum MA, Ashcroft M, Kubbutat MH, Vousden KH. Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. Curr Biol 2000; 10:539-42.
28. Weber HO, Samuel T, Rauch P, Funk JO. Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene 2002; 21:3207-12.
29. Manu M, Buckels J, Bramhall S. Molecular technology and pancreatic cancer. Br J Surg 2000; 87:840-53.
30. Sanchez-Cespedes M, Reed AL, Buta M, Wu L, Westra WH, Herman JG, Yang SC, Jen J, Sidransky D. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in nonsmall cell lung cancer. Oncogene 1999; 18:5843-9.
31. Gazzeri S, Della Valle V, Chaussade L, Brambilla C, Larsen CJ, Brambilla E. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res 1998; 58:3926-31.
32. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 2000; 14:2358-65.
33. 1 cell cycle arrest but augments p14 ARF-induced apoptosis in human carcinoma cells. Oncogene 2005; 24:4114-28.
34. Datta A, Nag A, Raychaudhuri P. Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF. Mol Cell Biol 2002; 22:8398-408.
35. Eymin B, Karayan L, Seite P, Brambilla C, Brambilla E, Larsen CJ, Gazzeri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 2001; 20:1033-41.
36. Karayan L, Riou JF, Seite P, Migeon J, Cantereau A, Larsen CJ. Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 2001; 20:836-48.
37. Jackson MW, Lindstrom MS, Berberich SJ. MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. J Biol Chem 2001; 276:25336-41.
38. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92:713-23.
39. Zhang WW. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther 1999; 6:113-8.
40. St George JA. Gene therapy progress and prospects: Adenoviral vectors. Gene Ther 2003; 10:1135-41.